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Executive Summary
Objective. The objective of this guideline is to provide rec-
ommendations for treating patients with the more common
forms of histoplasmosis.
Participants and consensus process. A working group of 8
experts in this ﬁeld was convened to develop this guideline.The
working group developed and reﬁned the guideline through a
series of conference calls.
Outcomes. The goal of treatment is to eradicate the infec-
tion when possible, although chronic suppression may be ad-
equate for patients with AIDS and other serious immunosup-
pressive disorders. Other important outcomes are resolution of
clinical abnormalities and prevention of relapse.
Evidence. The published literature on the management of
histoplasmosis was reviewed. Controlled trials have been con-
ducted that address the treatment of chronic pulmonary and
disseminated histoplasmosis, but clinical experience and de-
scriptive studies provide the basis for recommendations for
other forms of histoplasmosis.
Value. Value was assigned on the basis of the strength of
the evidence supporting treatment recommendations, with the
highest value assigned to controlled trials, according to con-
ventions established for developing practice guidelines.
Beneﬁts and costs. Certain forms of histoplasmosis cause
life-threatening illnesses and result in considerable morbidity,
whereas other manifestations cause no symptoms or minor self-
limited illnesses. The nonprogressive forms of histoplasmosis,
however, may reduce functional capacity, affecting work ca-
pacity and quality of life for several months. Treatment is
clearly beneﬁcial and cost-effective for patientswithprogressive
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forms of histoplasmosis, such as chronic pulmonary or dissem-
inated infection. It remains unknown whether treatment im-
proves the outcome for patients with the self-limited manifes-
tations, since this patient population has not been studied.
Other chronic progressive forms of histoplasmosis are not re-
sponsive to pharmacologic treatment.
Treatment options. Options for therapy for histoplasmosis
include ketoconazole, itraconazole, ﬂuconazole, amphotericin
B (Fungizone; Bristol-Meyer Squibb, Princeton,NJ),liposomal
amphotericin B (AmBisome; Fujisawa, Deerﬁeld, IL), ampho-
tericin B colloidal suspension (ABCD, or Amphotec; Seques,
Menlo Park, CA), and amphotericin B lipid complex (ABLC,
or Abelcet; Liposome, Princeton, NJ).
Introduction
Histoplasma capsulatum is endemic in certain areas of North
and Latin America, but cases have also been reported from
Europe and Asia. In the United States, most cases have oc-
curred within the Ohio and Mississippi River valleys. Precise
reasons for this endemic distribution pattern are unknown but
are thought to include moderate climate, humidity, and soil
characteristics. Bird and bat excrement enhances the growth of
the organism in soil by accelerating sporulation. These unique
growth requirements explain, in part, the localization of his-
toplasmosis intoso-calledmicrofoci.Activitiesthatdisturbsuch
sites are associatedwith exposuretoH.capsulatum.Aircurrents
carry the spores for miles, exposing individuals who were un-
aware of contact with the contaminated site. Furthermore, en-
vironmental sites that are not visibly contaminated with drop-
pings may harbor the organism, making it difﬁcult to suspect
histoplasmosis in most cases.
Severity of illness after inhalation exposure to H. capsulatum
varies, depending on theintensityofexposureandtheimmunity
of the host. Asymptomatic infection or mild pulmonary disease
follows low-intensity exposures in healthy individuals, whereas
heavy exposure may cause severe diffuse pulmonary infection.
Hematogenous dissemination from the lungs to other tissues
probably occurs in all infected individuals during the ﬁrst 2
weeks of infection before speciﬁc immunity has developed, butCID 2000;30 (April) Treatment of Histoplasmosis 689
Table 1. Indications for antifungal treatment in patients with histoplasmosis.
Treatment indicated Treatment not indicated
Acute pulmonary histoplasmosis with hypoxemia Acute self-limited syndromes
Acute pulmonary histoplasmosis for 11 month Acute pulmonary histoplasmosis, mildly ill
Chronic pulmonary histoplasmosis Rheumatologic
Esophageal compression and/or ulceration Pericarditis
Granulomatous mediastinitis with obstruction and/or invasion of tissue Histoplasmoma
Disseminated histoplasmosis Broncholithiasis
Fibrosing mediastinitis
a
a Antifungal therapy has not been proven to be effective for this form of histoplasmosis but should be considered,
especially in patients with elevated erythrocyte sedimentation rates or complement ﬁxation titers >1 : 32.
is nonprogressive in the majority of cases, which leads to the
development of calciﬁed granulomas in the liver and/or spleen.
Progressive dissemination occurs primarily in those with un-
derlying immunosuppressive disorders or those at the extremes
of age. Progressive pulmonary infection is common in patients
with underlying centrilobular emphysema. A variety of acute
and chronic manifestations of histoplasmosis appear to result
from unusual inﬂammatory or ﬁbrotic responses to the infec-
tion, including rheumatologic syndromes and pericarditis dur-
ing the ﬁrst year after exposure, and chronic mediastinal
inﬂammation or ﬁbrosis, broncholithiasis, and enlarging pa-
renchymal granulomas occurring later. A variety of treatment
options are available, but ﬁrst the decision must be made to
treat or to observe, since most patients with histoplasmosis
recover without therapy (table 1).
Speciﬁc Treatment Recommendations
Speciﬁc treatment recommendations for the more common
types of histoplasmosis are reviewed below and in table 2.
Acute Pulmonary Histoplasmosis
Fever, chills, headache, myalgia, anorexia, cough, and chest
pain characterize this form of histoplasmosis and are seen in
85%–100% of cases. Patients may experience pleuriticpain.The
ﬁndings on examination are usually unremarkable, except for
fever, but may include rales or pleural friction rubs.
The course after low-level exposure is benign in immuno-
competent patients. Symptomsusuallyabatewithinafewweeks
of onset [1]. Therapy may be helpful in symptomatic patients
whose conditions have not improved during the ﬁrst month of
infection. Fever persisting for 13 weeks in acute histoplasmosis
may indicate that the patient is developing progressive dissem-
inated disease, which may be aborted by therapy. Whether an-
tifungal therapy hastens recovery or prevents complications is
unknown, since it has never been studied in prospective trials.
Patients with diffuse radiographic involvement following
more intense exposure often experience more severe disease.
They may become hypoxemic and even require ventilatorysup-
port. Without treatment, recovery is usually slow and the out-
come may be fatal.
Localized pulmonary histoplasmosis. Treatment is not in-
dicated in the typical patient with acute pulmonary histoplas-
mosis because the illness is self-limited and associatedwithmin-
imal morbidity (EIII; see article by Sobel [2] for deﬁnitions of
categories reﬂecting the strength of each recommendation for
or against its use and grades reﬂecting the quality of evidence
on which recommendations are based).
Treatment with itraconazole, 200 mg once daily for 6–12
weeks, should be considered for patients who have shown no
clinicalimprovementafter1monthofobservation(BIII).Blood
concentrations of itraconazole obtained 2–4 h after adminis-
tration of a dose could be monitored in selected situations:
suspected treatment failure, concern about compliance or ab-
sorption, use of medications that may reduce the solubility of
itraconazole or accelerate its metabolism, and desire to reduce
the dose from 200 mg twice daily to 200 mg once daily. Al-
though the “therapeutic” concentration has not been deﬁned,
the MIC90 of itraconazoleforH.capsulatumis.02mg/mL,which
suggests that serum concentrations of 1 mg/mL measured by
bioassay should be therapeutic. Among AIDS patients, the me-
dian plasma concentration was about 6 mg/mL for patients
receiving a dosage of 200 mg twice daily and »3 mg/mL for
those receiving 200 mg once daily [3].
Diffuse pulmonary histoplasmosis in an immunocompetent
host. Amphotericin B, 0.7 mg/kg/d (or 1 of the lipid prepa-
rations at a dose of 3 mg/kg/d for patients with renal impair-
ment) should be used initially in those patients withmoresevere
manifestations who require ventilatory supportive therapy
(AIII). If amphotericin B is used exclusively because the patient
cannot be treated with oral medications, a total course of <35
mg/kg is recommended, but this situation is expected to be rare
(AIII).
The inﬂammatory response may contribute to the pathogen-
esis of the respiratory compromise; thus, corticosteroids may
be helpful, and prednisone could be administered at a dosage
of 60 mg daily for 2 weeks [4] (CIII). The role of corticosteroids
for treating extensive pulmonary histoplasmosis in the immu-
nocompromised host is less clear. Patients with AIDS and con-
current disseminated histoplasmosis and Pneumocystis carinii
pneumonia who received corticosteroids in conjunction with
treatment for both microbial pathogens did not appear to do
more poorly than other patients treated with antifungaltherapy
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Table 2. Summary of treatment recommendations for treatment of patients with histoplasmosis.
Type of histoplasmosis
Severe manifestation Moderately severe or mild manifestation
Treatment Class Treatment Class
Acute pulmonary AmB with corticosteroids,
a then Itr for 12 w AIII Symptoms !4 w: none; persistent symptoms
for 14 w: Itr for 6–12 w
EIII; BIII
Chronic pulmonary AmB,
b then Itr for 12-24 mo AII Itr for 12–24 mo AII
Disseminated in non-AIDS AmB,
b then Itr for 6–18 mo
c AII Itr for 6–18 mo AII
Disseminated in AIDS AmB,
b then Itr for life AII Itr for life AII
Meningitis AmB for 3 mo, then Flu for 12 mo BIII Same as for severe because of poor outcome BIII
Granulomatous mediastinitis AmB, then Itr for 6–12 mo BIII Itr for 6–12 mo BIII
Fibrosing mediastinitis Itr for 3 mo
d CIII Same as nonsevere CIII
Pericarditis Corticosteroids
e or pericardial drainage BIII Nonsteroidal anti-inﬂammatory agents
for 2–12 w
BIII
Rheumatologic Nonsteroidal anti-inﬂammatory agents
for 2–12 w
BIII Same as for severe BIII
NOTE. See article by Sobel [2] for deﬁnitions of categories reﬂecting the strength of each recommendation for or against its use and grades
reﬂecting the quality of evidence on which recommendations are based. AmB, amphotericin B; Flu, ﬂuconazole; Itr, Itraconazole.
a Effectiveness of corticosteroids is controversial (CIII)
b If amphotericin B is used for the entire course of treatment, 35 mg/kg should be given over 3–4 months.
c Therapy should continue until Histoplasma antigen concentrations are !4 units in urine and serum.
d Therapy is controversial and probably ineffective except in cases of granulomatous mediastinitis that are misdiagnosed as ﬁbrosing mediastinitis.
e If corticosteroids are administered; concurrent antifungal therapy is recommended (CIII).
After discharge from the hospital, itraconazole, 200 mg once
or twice daily, should be used to complete a 12-week course
(BIII).
Itraconazole alone, 200 mg once or twice daily for 6–12
weeks, could be used for patients who are not sufﬁciently ill to
require hospitalization (BIII).
Chronic Pulmonary Histoplasmosis
Patients with underlying lung disease may develop chronic
pulmonary infection after exposure to H. capsulatum. The clin-
ical and radiographic ﬁndings resemble those seen in reacti-
vation tuberculosis [5]. Without treatment, the illness is pro-
gressive, causing loss of pulmonary function in most patients
and death in up to half [5, 6]. In 1 study, although only 30%
of cases progressed after 1 year, 79% progressed with longer
observation [5]. Although some patients improve spontane-
ously, they remain at risk for recrudescence.
Treatment is indicated in all patients with chronicpulmonary
histoplasmosis. Studies have shown amphotericin B to be ef-
fective in 59%–100% of cases [6–14] (table 3). Ketoconazole
and itraconazole are effective in 75%–85% of case patients, but
their use is also complicated by high relapse rates [11–13]. Flu-
conazole, 200–400 mg daily, appears to be less effective (64%
response) than ketoconazole or itraconazole [14].
Itraconazole, 200 mg once or twice daily for 12–24 months,
is the treatment of choice for chronic pulmonaryhistoplasmosis
(AII).
Amphotericin B, 50 mg daily, or about 0.7 mg/kg/d, is rec-
ommended for patients who are judged to require hospitali-
zation because of ventilatory insufﬁciency or general debilita-
tion, inability to take itraconazole because of drug interactions
or allergies, inability to absorb itraconazole, inabilitytoachieve
detectable concentrations of itraconazole in the blood, or fail-
ure to improve clinically after at least 12 weeks of itraconazole
therapy (AII). Some patients may not be able to tolerate that
dosage of amphotericin B, which justiﬁes reducing the dosage
to 0.5–0.6 mg/kg/d or to use of 1 of the lipid formulations. If
amphotericin B is administered for the full course of therapy,
at least 35 mg/kg should be given at doses of 50 mg 3 times
weekly, if tolerated. In most patients, however, treatment can
be changed to itraconazole, 200 mg once or twice daily.
Fluconazole, 200–400 mg daily, is less effective than ampho-
tericin B or itraconazole and yielded a response rate of 64% in
1 study [14]. Fluconazole could be used in patients who cannot
receive itraconazole or are unable to achieve detectable blood
concentrations with itraconazole, but the dose should be in-
creased to 400–800 mg daily (BII). In a study of patients with
AIDS who had disseminated histoplasmosis, 800 mg daily was
used for histoplasmosis [15].
Ketoconazole (200 mg, 400 mg, or 800 mg daily) is reason-
ably effective but less well-tolerated than itraconazole or ﬂu-
conazole [12, 13]. Toxicity is more common in patientsreceiving
the 800 mg daily dosage, which is discouraged.
Disseminated Histoplasmosis
Underlying immunosuppressive conditions and extremes of
age are risk factors for dissemination, and illness is more severe
in immunocompromised individuals. Fever and weight loss are
the most common symptoms, and hepatomegaly or spleno-
megaly are common physical ﬁndings of disseminated histo-
plasmosis. Other frequent sites of dissemination include the
oropharyngeal or gastrointestinal mucosa, the skin, and the
adrenal glands. Shock, respiratory distress, hepatic and renal
failure, and coagulopathy may complicate severe cases [16].
CNS involvement occurs in 5%–20% of cases, presenting as
chronic meningitis or focal brain lesions. Histoplasma rarelyCID 2000;30 (April) Treatment of Histoplasmosis 691
Table 3. Outcome of antifungal therapy for patients with chronic
pulmonary histoplasmosis.
Reference
Antifungal
agent
No. of
patients
treated
Treatment outcome,
% of patients
Responded Relapsed Died
Furcolow [6] Amphotericin B 89 59 10 16
Putnam [9] Amphotericin B 32 100 NR NR
Sutliff [8] Amphotericin B 16 81 12 6
Baum [10] Amphotericin B 56 96 9 NR
Parker [7] Amphotericin B 238 99 15 NR
Dismukes [11] Itraconazole 20 80 15 5
Dismukes [12] Ketoconazole 23 74 4 NR
Slama [13] Ketoconazole 7 86 NR NR
McKinsey [14] Fluconazole 11 64 29 NR
NOTE. NR, not reported.
infects the spinal cord. The mortality without treatment is 80%
but can be reduced to !25% with antifungal therapy [6, 11–22]
(table 4). Treatment is indicated for all patientswithprogressive
disseminated histoplasmosis.
In studies that mostly included immunocompetent hosts and
speciﬁcally excluded those with AIDS, amphotericin B was ef-
fective in 68%–92% of patients [6, 17,18],itraconazole(200–400
mg daily) in 100% (only 10 patients studied) [11], ketoconazole
(200–400 mg daily) in 56%–70% [12, 13], and ﬂuconazole
(200–400 mg daily) in 86% [14] (table 4).
Among patients with AIDS, therapy with amphotericin B
was effective in 74%–88% of patients [19, 20], itraconazole (400
mg daily for 12 weeks) in 85% [21], ketoconazole (200–400 mg
daily) in 9% (only 11 cases) [16], and ﬂuconazole (800 mg daily
for 12 weeks) in 74% [15] (table 4). Of note, patients with severe
or moderately severe clinical manifestationswereexcludedfrom
the prospective studies that used itraconazole [21] and ﬂucon-
azole [15] but not from the retrospective reviews of patients
treated with amphotericin B. Of patients with severe disease,
nearly half died despite treatmentwith amphotericinB,whereas
98% of those with less severe illness responded to therapy [20].
There are no published reports about the use of the newer
lipid preparations of amphotericinB fortreatinghistoplasmosis
[16]. Most patients respond to therapy rapidly, with resolution
of fever in 1–2 weeks. Therapy is not curative for patients with
AIDS. Lifelong maintenance therapy is needed to prevent re-
lapse in patients with AIDS and disseminated histoplasmosis.
Amphotericin B, 50 mg given weekly or twice weekly, is highly
effective (81%–97%) but inconvenient and not well-tolerated
[16, 23]. Itraconazole, 200–400 mg daily, was effective in at
least 90% of cases [22]. Fluconazole, 100–400 mg daily was
effective maintenance therapy in 88% of patients with AIDS
who received amphotericin B induction therapy [24]. However,
in a prospective study, relapse occurred in nearly one-third of
patients who received ﬂuconazole, 400 mg daily, aftersuccessful
induction therapy with ﬂuconazole, 800 mg a day [15]. In vitro
resistance to ﬂuconazole developed in isolates from about half
of those patients who relapsed [15].
Immunocompetent hosts and immunocompromised hosts with-
out AIDS. Amphotericin B, 0.7–1.0 mg/kg/d is recommended
for patients who are sufﬁciently ill to require hospitalization
(table 2) (AII). Experience using the lipid formulations of am-
photericin B for treating histoplasmosis has not been reported.
Most patients respond quickly to amphotericin B and can then
be treated with itraconazole. The transition from amphotericin
B to itraconazole therapy could occur after the patientbecomes
afebrile, no longer requires blood pressure or ventilatory sup-
port or iv ﬂuids or nutrition, and is able to take oral medi-
cations. If amphotericin B is to be used for the full course, the
total dosage should be 35 mg/kg given over 2–4 months.
Itraconazole, 200 mg once or twice daily for 6–18 months,
is the treatment of choice for patients with mild or only mod-
erately severe symptoms who do not require hospitalization,
and for continuation of therapy in those whose condition has
improved in response to amphotericin B (AII).
Fluconazole should be used only in patients who cannot take
itraconazole (BII). The ﬂuconazole dosage should be at least
400 mg daily in nonimmunocompromised individuals and 800
mg daily in those with severe immunosuppressive conditions.
H. capsulatum may develop resistance to ﬂuconazole during
therapy, leading to relapse [25] and thus necessitating careful
follow-up assessment, including measurement of H. capsulatum
antigen concentration in blood and urine (BIII).
Ketoconazole, 200 mg once or twice daily, is also reasonably
effective (56%–70% response rate) but less well-tolerated than
itraconazole or ﬂuconazole [12, 13]. Ketoconazole could be
used in some situations where itraconazole is contraindicated
(BII).
Antigen testing may be useful for monitoring therapy in pa-
tients with disseminated histoplasmosis. Most of the data on
the use of the antigen test for monitoring therapy are derived
from studies of patients with AIDS. Antigen concentrations
decrease with therapy [16, 22] and increase with relapse [3, 26].
Some investigators recommend that treatment should be con-
tinued until antigen concentrations revert to negative or at least
reach low levels of <4 units. If treatment is stopped before
antigen concentrations in urine and serum revert to negative,
patients should be followed closely for relapse, and antigen
levels should be monitored every 3–6 months until they become
negative (BIII).
Patients with AIDS as the cause of immunosuppression.
Therapy is divided into an initial 12-week intensive phase to
induce a remission in the clinical illness and then followed by
a chronic maintenance phase to prevent relapse. A similar ap-
proach may be appropriate in other patients without AIDS
who have relapsed after appropriate courses of therapy.
For induction therapy, amphotericin B is recommended for
patients who are sufﬁciently ill to require hospitalization (table
2) (AII). Amphotericin B can be replaced with itraconazole,
200 mg twice daily (when the patient no longer requires hos-
pitalization or iv therapy), to complete a 12-week total course
of induction therapy.692 Wheat et al. CID 2000;30 (April)
Table 4. Outcome of antifungal therapy for patients with disseminated
histoplasmosis.
Reference(s)
Antifungal
agent
No. of
patients
treated
Treatment outcome,
% of patients
Responded Relapsed Died
Furcolow [6] Amphotericin B 22 68 9 23
Sathapatayavongs [19] Amphotericin B 43 74 7 16
Reddy [17] Amphotericin B 17 76 NR 23
Sarosi [18] Amphotericin B 24 91 20 8
Wheat [16, 20]
a Amphotericin B 73 88 19 12
Dismukes [11] Itraconazole 10 100 NR NR
Wheat [21, 22] Itraconazole 59 85 5 NR
Dismukes [12] Ketoconazole 31 56 10 NR
Slama [13] Ketoconazole 10 70 40 NR
Wheat [16]
a Ketoconazole 11 9 50 NR
Wheat [15] Fluconazole 49 74 31
b 2
McKinsey [14] Fluconazole 14 86 14 7
NOTE. NR, not reported.
a These studies were done in patients with AIDS.
b Relapses occurred in patients who responded to induction therapy and continued the
medication chronically for maintenance, although some of the relapses occurred in patients
who were not compliant with therapy or in those who were receiving rifampin.
Itraconazole, 200 mg 3 times daily for 3 days and then twice
daily for 12 weeks is the treatment of choice for patients who
have mild or moderately severe symptoms who do not require
hospitalization (AII).
Fluconazole, 800 mg daily, is an alternative for patients who
cannot take itraconazole (BII). Patients who are receiving ﬂu-
conazole should be followed closely clinically for relapse, and
antigen concentrations in urine and blood should be monitored
quarterly and at the time of suspected relapse (BIII).
For maintenance therapy, the treatment of choice is itracon-
azole 200 mg once or twice daily for life (AII). Antigen con-
centrations in serum and urine should be monitored every 3–6
months to provide evidence that maintenance therapy is con-
tinuing to suppress the progression of infection (BIII).
Amphotericin B, 50 mg iv once weekly, is an alternative but
is not as well-tolerated or accepted by patients and should be
reserved for patients who cannot take itraconazole (BII).
Fluconazole, 400–800 mg daily, could be used for patients
who cannot tolerate or do not absorb itraconazole and prefer
not to be treated with amphotericin B, but ﬂuconazole therapy
is discouraged because of its reduced efﬁcacy as chronic main-
tenance therapy for histoplasmosis (DII). Patients receivingﬂu-
conazole should be followed closely clinically for relapse, and
antigen concentrations in urine and blood should be monitored
quarterly and at the time of suspected relapse.
For prophylaxis in immunocompromised subjects, itracon-
azole is recommended. A trial comparing itraconazole, 200 mg
daily, versus placebo in patients with CD4
1 counts !150/mL
showed a 2-fold reduction in the incidence of histoplasmosis
in the itraconazole group, compared with the placebo group
(6.8%–2.7%) during a median follow-up period of 1 year [27].
In regions experiencinghighratesofhistoplasmosis(15cases/
100 patient-years), prophylaxis with itraconazole is recom-
mended (200 mg once daily) (BI). Fluconazole is not an ac-
ceptable alternative because of its inferior activity against H.
capsulatum, and lower efﬁcacy for treatment of histoplasmosis
[15].
CNS Histoplasmosis
Manifestations include meningitis, focal brain or spinal cord
lesions, cerebrovascular accident caused by vascular involve-
ment or cerebral emboli, and diffuse encephalitis [28]. Symp-
toms usually have been present for months to years before
diagnosis. Fever, headache, confusion, mental status changes,
seizures, or focal neurological deﬁcits may be seen. CSF ab-
normalities include lymphocytic pleocytosis, protein elevation,
and hypoglycorrhachia in patients with meningitis. Single or
multiple enhancing lesions may be seen by CT scan or MRI
in the brain or spinal cord of those with parenchymal involve-
ment [28].
The course of the disease is progressive and fatal if not
treated, although the speed of clinical deterioration is highly
variable [28]. The response to therapy is inferior to that in other
types of histoplasmosis: 20%–40% of patients with meningitis
succumb to the infection, despite treatment with amphotericin
B, and up to half of responders relapse after therapy is dis-
continued [28].
The optimal treatment for Histoplasma meningitis is un-
known, but an aggressive approach is recommended because
of the poor outcome.
Amphotericin B, 0.7–1 mg/kg/d to complete a 35 mg/kg total
dose over 3–4 months has been used most often (BIII). Flu-
conazole, 800 mg daily, might be continued for another 9–12
months after completion of amphotericin B, to reduce the risk
for relapse (BIII).
Liposomal amphotericin B (AmBisome), 3–5 mg/kg/d or
every other day given over a 3–4 month period might be con-
sidered for patients who have failed therapy with amphotericin
B followed by ﬂuconazole (CIII). In animal studies, liposomalCID 2000;30 (April) Treatment of Histoplasmosis 693
amphotericin B achieved higher concentrations in the blood
and brain than did amphotericin B or the other lipid formu-
lations [29], which provides a theoretical basis for its use in
meningitis. However, neither the lipid preparation nor ampho-
tericin B achieve detectable concentrations in CSF [29–31], and
none have been evaluated in cases of Histoplasma meningitis.
Chronic ﬂuconazole maintenance therapy, 800 mg daily,
should be considered for patients who relapse, despite full
courses of therapy, as described elsewhere (CIII).
Itraconazole, although more active than ﬂuconazole against
H. capsulatum, does not enter the CSF, which makes it a less-
appealing choice for treatment of meningitis and discourages
its use for this indication (DIII). Of note, however, the role of
CSF concentrations of antifungal agents in the outcome of
treatment of fungal meningitis is unclear.
Patients who relapse despite chronicmaintenancetherapyare
candidates for administration of amphotericin B directly into
the ventricles, cisterna magna, or lumbar arachnoid space. Ex-
perience using intrathecal or intraventricular therapy, however,
has not been encouraging; this approach to therapy is dis-
couraged except for patients for whom all other approaches to
therapy have failed [28] (DIII).
Focal involvement of the brain or spinal cord in the absence
of meningitis may be more responsive to antifungal therapy.
Of 6 such cases in persons without AIDS, all responded to
amphotericin B therapy, but 2 relapsed [28]. Amphotericin B
is recommended for the initial therapy (BIII). Penetration of
the CSF may not be required for successful therapy of paren-
chymal lesions; thus itraconazole, 200 mg 2 or 3 times daily,
may be appropriate after the patients’ conditions have im-
proved with amphotericin B (CIII).
Parenchymal lesions rarely require surgical excision [28]
(DIII).
Granulomatous Mediastinitis
Symptoms that include chest pain, cough, hemoptysis, and
dyspnea may be caused by compression of the airways,superior
vena cava, or pulmonary vesselsinpatientswithgranulomatous
mediastinitis. These syndromes represent active inﬂammation
of the mediastinal lymph nodes rather than ﬁbrotic reactions
to past infection. Although symptoms are often mild and re-
solve over a few months, they may be more severe and pro-
tracted. Antifungal therapy has been helpful in some cases [32,
33]. Adjunctive treatment with corticosteroidsappearedtohave
been beneﬁcial in 1 patient who had airway obstruction [34].
Resection of obstructive masses is another approach that has
been helpful for patients with granulomatous mediastinitis
[35–38]
Amphotericin B, 0.7–1.0 mg/kg/d, should be considered as
initial therapy for patients with severe obstructive complica-
tions of mediastinal histoplasmosis (BIII). Therapy could be
changed to itraconazole, 200 mg once or twice daily, after im-
provement is sufﬁcient for outpatient treatment.
Itraconazole, 200 mg once or twice daily for 6–12 months,
is recommended for patients with milder manifestations that
persist for 11 month (table 3) (BIII).
Prednisone, 40–80 mg daily for 2 weeks, could be considered
in those with major airway obstruction (CIII).
Surgical resection of the mediastinal mass should be reserved
for patients who remain symptomatic and continue to dem-
onstrate obstruction of major mediastinal structures, despite a
trial of antifungal therapy (BIII).
Fibrosing Mediastinitis
Fibrosing mediastinitis is a late complication of histoplas-
mosis arising from nodal regions and ultimately invasion and
occlusion of the central vessels and airways. Patients often re-
port symptoms of several years’ duration at the time of diag-
nosis. The course is progressive and often fatal [39, 40]. Al-
though most authorities believe that neither antifungal nor
anti-inﬂammatory treatment ameliorates the outcome of ﬁ-
brosing mediastinitis [39, 40], others have reported improve-
ment after antifungal therapy [41].
Information is inadequate on which to make ﬁrm treatment
recommendations. The progressive course of this syndrome,
however, makes it difﬁcult to withhold antifungal therapy. If
the clinical ﬁndings are consistent with a more acute inﬂam-
matory process rather than a chronic ﬁbrotic process,especially
if complement ﬁxation titers and the erythrocyte sedimentation
rate are elevated, treatment may be helpful.
A 12-week trial of itraconazole, 200 mg once or twice daily,
is suggested if clinical ﬁndings do not differentiate ﬁbrosing
mediastinitis from granulomatous mediastinitis (CIII). Patients
who truly have ﬁbrosing mediastinitis are not expected to re-
spond to antifungal therapy. The only basis to prolong therapy
beyond 12 weeks would beclearcutradiographicdemonstration
of abatement of obstruction, in which case therapy could be
continued for 1 year.
Corticosteroid therapy has not been helpful when tried [39,
42, 43] and is discouraged (DIII).
Surgery should be approached with great caution in patients
with severe complications of ﬁbrosing mediastinitis and only
in those who are expected to succumb from the condition with-
out intervention. Surgeons experienced in the management of
ﬁbrosing mediastinitis should be consulted (CIII).
Placement of intravascular stents has been helpful in some
patients with superior vena cava, pulmonary artery, or pul-
monary vein obstruction, and might be tried in patients with
severe manifestations (CIII).
Pericarditis
Pericarditis occurs in 5%–10% of patients with acute histo-
plasmosis and appears to be caused by the inﬂammatory re-
sponse to the infection rather than the infection per se. These
manifestations rarely may be a complication of disseminated694 Wheat et al. CID 2000;30 (April)
histoplasmosis [44]. Patients with pericarditis respond to non-
steroidal anti-inﬂammatory agents without antifungal therapy,
but those with pericardial tamponade often require percuta-
neous or surgical drainage of the pericardial ﬂuid [44]. Long-
term outcome is excellent, with only rare progression to con-
strictive pericarditis [44].
Antifungal therapy is not recommended (DIII).
Therapy with nonsteroidal anti-inﬂammatory agents is rec-
ommended for 2–12 weeks, on the basis of clinical resolution
of the symptoms and physical ﬁndings of pericarditis (BIII).
Corticosteroids might be tried for 1–2 weeks in patients with
hemodynamic compromise, followed by continued treatment
with nonsteroidal anti-inﬂammatory agents, until the clinical
ﬁndings and radiographic evidence of cardiomegaly resolved
(CIII). Concurrent itraconazole, 200 mg once or twice daily for
12 weeks, could be given along with corticosteroids, to reduce
the concern that corticosteroids might promote progression of
the infection (CIII).
Percutaneous or surgical drainage is recommended for pa-
tients with more severe ﬁndings of pericardial tamponade or
with moderately severe evidence of hemodynamic compromise
that does not respond to corticosteroids (AIII).
There is no evidence that antifungal, anti-inﬂammatory, or
surgical therapy prevents constrictive pericarditis (DIII).
Rheumatologic Syndromes
The arthritis is polyarticular and symmetrical in half of cases
and involves joints of the upper and lower extremities with
similar frequency. Nearly half of patients with rheumatologic
manifestations exhibit erythema nodosum and/or erythema
multiforme [45, 46]. The joint symptoms usually resolve in re-
sponse to treatment with nonsteroidal anti-inﬂammatory
agents.
Antifungal therapy is not recommended (DIII).
Therapy with nonsteroidal anti-inﬂammatory agents is rec-
ommended for 2–12 weeks, on the basis of resolution of the
symptoms and physical ﬁndings of arthritis and erythema no-
dosum (BIII). Relapse may occur after anti-inﬂammatory ther-
apy is stopped, thus requiring reinstitution for another 4–8
weeks.
Histoplasmosis During Pregnancy
Pregnant women with histoplasmosis should not be treated
with azole antifungal agents because of the potential of this
class of drugs to cause teratogeniccomplications.Amphotericin
B, however, is safe during pregnancy and is the treatment of
choice for such cases. The safety of the lipid preparations of
amphotericin B during pregnancy is unknown. There is no ev-
idence that histoplasmosis is more severe during pregnancy or
that dissemination occurs to the fetus.
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